Haley Gittleman1,2, Gino Cioffi1,2, Toni Vecchione-Koval3, Quinn T Ostrom1,4, Carol Kruchko1, Diana S Osorio5,6, Jonathan L Finlay5,6, Jill S Barnholtz-Sloan7,8. 1. Central Brain Tumor Registry of the United States, Hinsdale, IL, USA. 2. Department of Population and Quantitative Health Sciences, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 11100 Euclid Ave, Wearn 152, Cleveland, OH, 44106-5065, USA. 3. Sargent College, Boston University, Boston, MA, USA. 4. Department of Medicine, Section of Epidemiology and Population Sciences, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA. 5. The Neuro-Oncology Program, Division of Hematology, Oncology and BMT, Nationwide Children's Hospital, The Ohio State University, Columbus, OH, USA. 6. Department of Radiation Oncology, Ohio State University, Columbus, OH, USA. 7. Central Brain Tumor Registry of the United States, Hinsdale, IL, USA. jsb42@case.edu. 8. Department of Population and Quantitative Health Sciences, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, 11100 Euclid Ave, Wearn 152, Cleveland, OH, 44106-5065, USA. jsb42@case.edu.
Abstract
PURPOSE: Germ cell tumors (GCT) in the central nervous system (CNS) are rare tumors that occur with highest frequency in males, Asian populations, and children less than age 20 years. Due to the rarity of these tumors, their patterns of incidence are not well-described. The aim of this study is to provide the most up-to-date data on incidence and survival patterns for CNS GCT by sex, race, and age at diagnosis. METHODS: The Central Brain Tumor Registry of the United States (CBTRUS) is the largest aggregation of population-based incidence data on primary brain and other CNS tumors in the United States, containing incidence data from 51 central cancer registries and representing 100% of the US population. The current study used the CBTRUS analytic file to examine incidence (IR) of CNS GCT from 2006 to 2015, as well as registry data from the Surveillance, Epidemiology, and End Results (SEER) program to examine survival. RESULTS: Males had greater IR than females in all CNS GCT histologies examined. Asian and Pacific Islanders had a significantly greater IR of CNS GCT than the other race categories. We confirmed that CNS GCT IR was greatest for those age 10-14 years and male. Overall survival rates were high for malignant CNS GCT, germinoma, mixed GCT, and malignant teratoma. CONCLUSIONS: There is significant variation in CNS GCT incidence by sex, race, and age at diagnosis. Ascertaining accurate incidence and survival rates of CNS GCT provides vital information usable in real time for clinicians, public health planners, patients, and their families.
PURPOSE: Germ cell tumors (GCT) in the central nervous system (CNS) are rare tumors that occur with highest frequency in males, Asian populations, and children less than age 20 years. Due to the rarity of these tumors, their patterns of incidence are not well-described. The aim of this study is to provide the most up-to-date data on incidence and survival patterns for CNS GCT by sex, race, and age at diagnosis. METHODS: The Central Brain Tumor Registry of the United States (CBTRUS) is the largest aggregation of population-based incidence data on primary brain and other CNS tumors in the United States, containing incidence data from 51 central cancer registries and representing 100% of the US population. The current study used the CBTRUS analytic file to examine incidence (IR) of CNS GCT from 2006 to 2015, as well as registry data from the Surveillance, Epidemiology, and End Results (SEER) program to examine survival. RESULTS: Males had greater IR than females in all CNS GCT histologies examined. Asian and Pacific Islanders had a significantly greater IR of CNS GCT than the other race categories. We confirmed that CNS GCT IR was greatest for those age 10-14 years and male. Overall survival rates were high for malignant CNS GCT, germinoma, mixed GCT, and malignant teratoma. CONCLUSIONS: There is significant variation in CNS GCT incidence by sex, race, and age at diagnosis. Ascertaining accurate incidence and survival rates of CNS GCT provides vital information usable in real time for clinicians, public health planners, patients, and their families.
Authors: Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen Journal: Nat Rev Dis Primers Date: 2022-04-21 Impact factor: 52.329
Authors: T Feola; R Sa Pirchio; G Puliani; R Pofi; M Crocco; V Sada; F Sesti; F Verdecchia; D Gianfrilli; M Appetecchia; N Di Iorgi; M L Jaffrain-Rea; R Pivonello; A M Isidori; A B Grossman; E Sbardella Journal: J Endocrinol Invest Date: 2022-08-24 Impact factor: 5.467
Authors: Quinn T Ostrom; Gabrielle Truitt; Haley Gittleman; Daniel J Brat; Carol Kruchko; Reda Wilson; Jill S Barnholtz-Sloan Journal: Neurooncol Pract Date: 2019-12-16
Authors: Camille K Milton; Panayiotis E Pelargos; Nathaniel D Stetson; Manuel Maldonado-Vital; Kar-Ming A Fung; Ian F Dunn Journal: Rare Tumors Date: 2021-06-20
Authors: Sydni M Cole; Sasmit Sarangi; David Einstein; Malgorzata McMasters; Ron Alterman; Jeffrey Bruce; Lauren Hertan; Helen A Shih; Eric T Wong Journal: Surg Neurol Int Date: 2021-05-25